Stockholm, March 29, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2-receptor agonists (ATRAGs), today announces that the UK MHRA (Medicines and Healthcare products Regulatory Agency) has awarded Vicore Innovation Pa... read more

March 28, 2023 Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has received a research grant of 3 MSEK from Sweden´s Innovation... read more

HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in ... read more

CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Tilda... read more

Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients St... read more